- Home
- STIM vs XGN Comparison
STIM vs XGN Comparison
Compare STIM & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STIM
- XGN
- Stock Information
- Founded
- STIM 2003
- XGN 2002
- Country
- STIM United States
- XGN United States
- Employees
- STIM N/A
- XGN N/A
- Industry
- STIM Medical/Dental Instruments
- XGN Medical Specialities
- Sector
- STIM Health Care
- XGN Health Care
- Exchange
- STIM Nasdaq
- XGN Nasdaq
- Market Cap
- STIM 224.8M
- XGN 210.4M
- IPO Year
- STIM 2018
- XGN 2019
- Fundamental
- Price
- STIM $2.90
- XGN $10.88
- Analyst Decision
- STIM Strong Buy
- XGN Strong Buy
- Analyst Count
- STIM 2
- XGN 5
- Target Price
- STIM $7.00
- XGN $12.40
- AVG Volume (30 Days)
- STIM 1.2M
- XGN 248.4K
- Earning Date
- STIM 11-11-2025
- XGN 11-11-2025
- Dividend Yield
- STIM N/A
- XGN N/A
- EPS Growth
- STIM N/A
- XGN N/A
- EPS
- STIM N/A
- XGN N/A
- Revenue
- STIM $111,106,000.00
- XGN $58,862,000.00
- Revenue This Year
- STIM $105.70
- XGN $22.28
- Revenue Next Year
- STIM $11.77
- XGN $14.03
- P/E Ratio
- STIM N/A
- XGN N/A
- Revenue Growth
- STIM 54.17
- XGN 3.89
- 52 Week Low
- STIM $0.52
- XGN $2.38
- 52 Week High
- STIM $5.92
- XGN $11.17
- Technical
- Relative Strength Index (RSI)
- STIM 47.33
- XGN 63.84
- Support Level
- STIM $2.58
- XGN $9.30
- Resistance Level
- STIM $3.01
- XGN $11.11
- Average True Range (ATR)
- STIM 0.18
- XGN 0.43
- MACD
- STIM 0.04
- XGN 0.04
- Stochastic Oscillator
- STIM 78.16
- XGN 84.17
About STIM Neuronetics Inc.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.